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Since the discovery of chlorpromazine in 1950, antipsychotics play a crucial role in the 
treatment of psychotic disorders[1]. Since then many new antipsychotics have been 
introduced to the market. They are commonly categorized into First-Generation Anti-
psychotics (FGAs) and Second-Generation Antipsychotics (SGAs). FGAs were developed 
in the 1950s and 1960s and the SGAs emerged in the 1980s[1].  
Although FGA are very effective in the treatment of psychotic disorders, many pa-
tients developed movement disorders as a side effect[2]. However, an exception, al-
ready developed in the sixties, was clozapine, a new antipsychotic that induced far less 
movement disorders than FGAs. Clozapine was considered as the first of a new genera-
tion of antipsychotics[3, 4].  
The most common movement disorders observed in patients with psychotic disor-
ders are parkinsonism, akathisia, dyskinesia and dystonia[2, 5]. These movement disor-
ders are a serious burden on patients; they can cause distress (especially feelings of 
shame) and (physical) discomfort in patients and often contribute to medication non-
compliance[5]. 
This chapter begins with a summary of our studies on the epidemiology of move-
ment disorders in the GROUP study and the switch to clozapine monotherapy as a 
treatment for tardive dyskinesia. The second part of this chapter summarizes our re-
search on the use of digital/electronic instruments to assess and monitor movement 
disorders. 
Epidemiology of Movement Disorders 
The epidemiology of movement disorders in patients on long-term treatment with first 
generation antipsychotics has been studied thoroughly[2, 6]. However, less is known 
about the incidence and prevalence of movement disorders in patients who just started 
treatment with antipsychotics, and especially with second-generation antipsychotics[7]. 
The first years of treatment are especially interesting to study, as the neural pathways 
that are associated with movement disorders are still relatively unaffected by the long-
term potentiation effects of antipsychotic treatment. Therefore, we studied the inci-
dence, prevalence, persistence and clinical correlates of parkinsonism, akathisia, dyski-
nesia and dystonia in a large cohort of relatively young adults, the Genetic Risk and 
Outcome of Psychosis (GROUP) study[8]. Surprisingly, we found that although the ma-
jority of patients in the cohort were treated exclusively with SGAs as many as 40% de-
veloped a movement disorder. The incidence, prevalence and persistence rates of 
movement disorders in the GROUP study are lower than the rates reported by studies 
that investigated older populations treated with first generation antipsychotics[2, 5, 6, 
9, 10] and slightly higher than studies investigating SGAs in similar populations[4, 11]. 
The severity of parkinsonism was correlated to IQ scores, severity of akathisia, severity 
of dyskinesia, and the severity of the negative symptoms of schizophrenia (i.e. reduc-
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tions in emotional responsiveness, motivation and both verbal and physical expression). 
This is in line with other studies [6, 12-15]. Correlations were also observed between 
the degree of the positive symptoms of schizophrenia (i.e. delusions and hallucinations) 
and the severity of akathisia and dyskinesia. Another interesting finding in our study was 
the absence of a dose-response relation between antipsychotics and movement disor-
ders. The association between the severity of movement disorders and the type of 
antipsychotic medication was also absent. Yet, we did observe that the patients treated 
with more than one antipsychotic drug had more severe movement disorders than the 
patients treated with a single antipsychotic. Altogether, these findings show that 
movement disorders are frequently present in a large, relatively young population that 
predominantly used SGAs. Thus movement disorders remain a serious concern as they 
negatively impact the quality of life of patients. This underscores the importance of 
monitoring for movement disorders in patients with schizophrenia or other psychotic 
disorders.  
The effect of switching to clozapine treatment on Tardive Dyskinesia 
Tardive dyskinesia develops months to years after antipsychotic treatment has been 
started and it can persist after discontinuation of treatment[5, 10]. Tardive dyskinesia is 
believed to be caused by a long-term effect of antipsychotic treatment on the parts of 
the dopamine system involved in regulating movement[16, 17]. Two dominant etiologi-
cal hypotheses of tardive dyskinesia are a dysregulation of neurons in the basal ganglia 
involved with motor control either due to hyper-sensitization or cell damage caused by 
the production of free radicals[16, 17]. Several proposed treatments for tardive dyski-
nesia (i.e. anticholinergics, benzodiazepines, calcium channel blockers and vitamin E 
supplementation) lack convincing evidence[18-21]. Switching current antipsychotic 
treatment to clozapine monotherapy has also been suggested as a potential treatment 
for tardive dyskinesia[16, 22, 23]. However, there are no meta-analyses dedicated to 
investigating clozapine as a potential treatment for tardive dyskinesia. Therefore, we 
performed a meta-analysis to study the effect of switching to clozapine on the severity 
of tardive dyskinesia. We opted to use a broad search strategy that included studies 
that investigated the effect of switching to clozapine with tardive dyskinesia as the pri-
mary study outcome and studies with tardive dyskinesia as a secondary outcome. The 
reason we also included studies with tardive dyskinesia as a secondary outcome was 
because we expected to find few studies that investigated the switch to clozapine as a 
treatment for tardive dyskinesia and the findings of the studies with tardive dyskinesia 
as a secondary outcome could have contradicted the findings of the other studies. This 
search returned more than 10.000 hits of which only 17 studies met our inclusion crite-
ria and could be included in our meta-analysis. Only 4 of the 17 studies investigated 
tardive dyskinesia as a primary outcome. These four studies showed, convincingly, that 
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switching to clozapine can substantially reduce the severity of moderate to severe tar-
dive dyskinesia, and in many cases even alleviate dyskinetic symptoms completely. The 
other studies showed that a switch to clozapine monotherapy is not likely to worsen the 
severity of tardive dyskinesia in patients with mild to no dyskinetic symptoms. Thus, our 
findings make a strong case for switching to clozapine monotherapy to treat tardive 
dyskinesia in patients with moderate to severe dyskinetic symptoms.  
Instrumental Assessments of Movement disorders 
When studying movement disorders it is important to quantify their severity using valid 
and reliable methods. The second part of this thesis focuses on using digital/electronic 
instruments to assess and monitor movement disorders. A wide range of digi-
tal/electronic instruments have already been developed to assess and monitor move-
ment disorders. However, the adoption of these instruments into clinical practice has 
been minimal. Therefore, we set out to develop a number of instrumental assessments 
suitable for use in a regular clinical setting. We aimed to keep these instruments easy to 
use and affordable while being more sensitive and reliable than conventional scales. 
Four instruments were developed that utilize the latest technologies: (i) A bradykinesia 
assessment that is similar to conventional observer based scales, but uses inertial sen-
sors to assess the severity of bradykinesia. (ii) A redesign of an instrument that 
measures variability in force, a sign of dyskinesia. (iii) An instrument that uses a depth 
camera to automate the assessment of orofacial dyskinetic signs. (iv) An app that in-
cludes several touch based tasks aimed at assessing signs of movement disorders and 
other soft motor signs (Neurological Soft Signs). Four studies were conducted with 
these instruments, three studies investigated the feasibility of these instruments (i, iii & 
iv) and one study determined the validity and reliability of the instrument for assessing 
bradykinesia (i). 
Recent studies have shown that inertial sensors can reliably capture and assess the 
movements of tasks used by conventional rating scales that assess the motor signs of 
Parkinson’s Disease[24-26]. Considering that the signs of parkinsonism are very similar 
to those of Parkinson’s Disease we investigated the feasibility of an instrument for the 
assessment of antipsychotic-induced bradykinesia. Performances on a wide range of 
motor tasks were compared between six bradykinetic patients and five healthy controls. 
These tasks were derived from common observation based rating scales such as the St. 
Hans Rating Scale and the Unified Parkinson’s Disease Rating Scale. The patients per-
formed significantly worse than the controls on seven of the thirteen tasks. The combi-
nation of tasks we deem the most feasible includes walking 20 metres, rapidly bend-
ing/stretching the elbow, rotating the lower arm and stomping the foot on the ground. 
Combining these four tasks distinguished patients from controls very effectively. The 
validity and reliability of these four tasks were determined in a subsequent study. To 
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investigate the validity of the bradykinesia assessment by our instrument, we deter-
mined its concurrent validity with the bradykinesia items of the Unified Parkinson’s 
Disease Rating Scale in 64 in-patients with a psychotic disorder and varying degrees of 
bradykinesia. Our findings show that the validity of the instrument’s assessments is 
high. We also found that the instrument’s test-retest reliability is excellent. This shows 
that it is feasible to assess antipsychotic-induced bradykinesia validly and reliably using 
our instrument. 
Reliable assessment of the orofacial signs of dyskinesia is difficult and requires a 
substantial frame of reference. Inspired by a previous study we designed a method to 
automate the assessment of dyskinetic movements that occur in the facial 
musculature[27]. Instead of using a regular camera we used an infrared depth camera, 
as this type of camera can reliably capture facial movement without the need to place 
markers. The faces of five dyskinetic patients and five healthy controls were filmed with 
a Kinect camera while they rested or performed a motor task to distract them. The data 
recorded by the Kinect showed that there was significantly more movement in the lips 
of the patients than of the controls. In other regions of the face differences were not 
significant, because the Kinect could not detect subtle movements reliably enough in 
these regions. Currently, it is not yet feasible to assess orofacial dyskinesia, as not all 
signs can be recorded reliably. However, it is likely that this method will soon become 
more feasible with improvements to the algorithm that tracks the movement of the 
facial regions and increases in the resolution of depth cameras.  
The widespread adoption of smartphones and tablets make them ideal for screening 
motor signs in large groups. Screening for motor symptoms could help improve the 
detection of individuals at risk of developing a psychotic disorder[28]. Several signs 
related to movement disorders and neurological soft signs are elevated in these indi-
viduals in comparison to their healthy peers[29, 30]. We developed an app that uses 
several touchscreen based tasks derived from existing instruments and rating scales. 
The feasibility of these tasks was determined by first investigating whether these tasks 
are capable of reliably detecting very subtle differences in these motor signs. To deter-
mine the discriminability and reliability of these tasks we compared scores on these 
tasks between 10 young and 6 middle-aged adults. The results demonstrate that several 
of these tasks are capable of detecting very subtle differences in reaction time, move-
ment speed and the planning and accuracy of movement. As the reaction time, the 
tracing and the trail making tasks differed significantly between young and middle-aged 
adults. The discriminability, reliability, ease of use and low cost of this tablet based 
assessment warrants further research; further investigation whether or not these tasks 
can be used to screen for subtle motor signs in individuals with an increased risk of 
developing a psychotic disorder is recommended. 
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General Discussion  
This thesis expands the knowledge of movement disorders related to psychosis in epi-
demiological, treatment and diagnostic areas. First, a large prospective study in a rela-
tively young population using predominantly SGA shows that movement disorders are 
frequently present. Second, a meta-analysis of the effect of a switch to clozapine in 
patients with tardive dyskinesia shows that this intervention is very effective. Third, 
innovative and feasible instruments have been developed to measure parkinsonism and 
tardive dyskinesia.  
GROUP study 
The epidemiological study of movement disorders in the GROUP cohort shows that, in 
contrast to what is often suggested, movement disorders are also frequent in young 
adults treated with SGAs. A surprising outcome of the investigation of the clinical corre-
lates of movement disorders was that there was no significant association between the 
type of antipsychotic treatment, FGA or SGA, and the severity of movement disorders. 
An explanation for the lack of the association between antipsychotic treatment and 
severity could be that it was overseen due the combination of the relatively long time 
(three years) between measurements and the naturalistic design of the GROUP study. 
On the other hand, it may be possible that not all movement disorders are directly 
caused by antipsychotic treatment but that they are integral symptoms to schizophre-
nia. This idea is supported by antipsychotic naïve patients with a first episode psychotic 
disorder, who also had movement disorders [31]. Moreover, our results show that par-
kinsonism may be interrelated with the mental and cognitive symptoms of schizophre-
nia. Both findings support the hypothesis that movement disorders are, at least partial-
ly, integral to schizophrenia. Considering that nearly 40% of the patients in the GROUP 
cohort had a movement disorder, there is a strong need to regularly monitor movement 
disorders in patients with psychotic disorders. Even if the actual prevalence of move-
ment disorders may be somewhat lower than our findings suggest[4, 11] they are still a 
frequent and serious burden.  
Tardive dyskinesia 
Tardive dyskinesia can be a very persistent movement disorder. Several studies have 
investigated treatments for managing its symptoms[18-21], but these treatments lack 
convincing evidence. The results from our meta-analysis show that switching to clozap-
ine can effectively reduce dyskinetic symptoms. This is remarkable because with the 
exception of olanzapine[22] this does not appear to be the case for other antipsychot-
 128 
ics. The mechanisms behind the effectivity of clozapine as a treatment for tardive dyski-
nesia remains unknown. A possible explanation is that clozapine’s unique receptor pro-
file or that its cholinergic effects revert the hypersensitisation or damage of the striatal 
neurons involved with movement. However, neither PET nor SPECT imaging studies 
clearly support these explanations[32]. Another explanation for the efficacy of clozap-
ine, yet to be explored by PET studies, is that clozapine may regulate presynaptic dopa-
minergic function differently than other antipsychotics[32]. Clozapine is a very effective 
antipsychotic, but a switch to clozapine has some drawbacks. Clozapine may induce or 
worsen metabolic problems and requires regular blood tests due to the increased risk of 
agranulocytosis[33]. Therefore, clozapine is typically only prescribed when patients do 
not respond to, or do not tolerate other antipsychotics. However, there are many cases 
in which the burden of TD outweighs the risks of clozapine treatment and in these cases 
switching to clozapine could provide considerable relief. 
Instrumental assessment of movement disorders 
There are some practical inconveniences to regular monitoring of movement disorders. 
Monitoring can be time consuming and expensive, as it requires regular training of staff 
to achieve valid and reliable results. Fortunately, this can be improved substantially with 
the application of instrumental assessments. These instruments can make screening of 
movement disorders easier and more efficient and the reliability of these assessments 
is far less dependent on the experience and training of the assessor. Thus, monitoring 
can be off loaded to other staff members, freeing up the costly time of clinicians. There 
are even instruments that are capable of registering signs of movement abnormalities 
that are too subtle to be detected by the clinical rating scales. The potential of these 
instruments is tremendous as more and more studies show that movement disorders 
are more than just a side effect of the antipsychotic medication[31, 34-36]. For drug-
induced movement disorders detecting subtle signs can help to detect and prevent 
movement disorders from developing further by treating them earlier.  
Subtle movement disorders that are present in antipsychotic naïve patients of pa-
tients at risk for psychosis have prognostic value[37]. In patients at risk of psychosis 
subtle movement disorders predict conversion to psychosis and in antipsychotic naïve 
patients, parkinsonian symptoms predict worse outcome compared to antipsychotic 
naïve patients without parkinsonism[38-42]. The association between movement disor-
ders and the severity of psychosis has also been shown in brain imaging studies, the 
presence of subtle movement disorders in the early stages (pre-clinical) of psychotic 
disorders has been been linked to structural brain abnormalities related to the severity 
of positive and negative symptoms[35].  
Another advantage of detecting movement disorders is that they are objective signs 
in contrast to most other symptoms in individuals with pre-clinical psychotic disorders 
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that are obtained with questionnaires. Screening for movement disorders in these 
groups may improve the specificity of a screening process. Nevertheless, clinical adop-
tion of instrumental assessments for movement disorders remains limited. Instruments 
intended for routine assessment of movement disorders in a clinical setting must regis-
ter movement disorders reliably, while they also must be affordable, portable and user 
friendly. Not all instruments meet these criteria, but with the introduction of novel 
instrumental assessments this is changing rapidly.  
We predict that the implementation of devices and instruments will become wide-
spread in clinical practice over the next decade. Our expectations are that using the 
next iterations of wearable devices such as smartwatches, fitness trackers and smart 
textiles in combination with machine learning algorithms will greatly improve the as-
sessment and monitoring of movement disorders. The ability to assess movement dis-
orders continuously can place them in context with the fluctuations of other symptoms 
(mental and cognitive), potential biomarkers (proteins in sweat[43]), and external influ-
ences. 
This thesis has shown that movement disorders not only occur frequently in elderly 
patients on FGAs but also in younger patients on SGAs, that switching to clozapine is an 
important consideration for the treatment of tardive dyskinesia, and that instrumental 
assessment is an accurate and valid way for monitoring movement disorders. It would 
be interesting to see whether improvements in the instrumental assessment of move-
ment disorders may change the outcome of patients with psychotic disorders. Would 
early detection prevent the development of drug induced movement disorders or the 
conversion to a psychotic disorder or improve the outcome of a first episode?  
Another interesting direction for future research would be to gain more insights into 
the prognostic potential of monitoring and screening for movement disorders. Future 
studies could combine daily assessments of movement disorders with daily assessments 
of mental and cognitive symptoms, related biomarkers and changes in the environment 
via a combination of wearable sensors and experience sampling. This will lead to greater 
understanding of the course of schizophrenia and could establish movement disorders 
as an objective non-mental sign with high clinical relevance[42].  
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